Literature DB >> 12373418

Convulsant activity of a non-peptidic delta-opioid receptor agonist is not required for its antidepressant-like effects in Sprague-Dawley rats.

Daniel C Broom1, Emily M Jutkiewicz, John E Folk, John R Traynor, Kenner C Rice, James H Woods.   

Abstract

RATIONALE: Non-peptidic delta-opioid receptor agonists possess antidepressant-like activity in the forced swim assay in the rat. These compounds have also previously been shown to possess convulsant properties in mice.
OBJECTIVE: The aim of the present study was to examine whether such convulsions occurred in rats and to investigate if delta-mediated convulsant activity was necessary for the mediation of delta-opioid agonist-induced antidepressant-like activity.
METHODS: The peripheral administration of delta-opioid receptor agonists to male Sprague-Dawley rats was followed by a period of observation for convulsant activity. Following this period and 60 min after delta-opioid agonist administration, rats were tested in the forced swim assay.
RESULTS: The non-peptidic delta-opioid receptor agonists (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-methoxyphenyl)methyl]-N,N-diethylbenzamide (SNC80) and (+)-4-[(R)-[(2S,5R)-2,5-dimethyl-4-(2-propenyl)-1-piperazinyl]-(3-hydroxyphenyl)methyl]-N,N-diethylbenzamide dihydrochloride [(+)BW373U86] both produced dose-dependent convulsant activity in rats and decreased immobility in the forced swim assay. The delta-opioid receptor antagonist naltrindole prevented the convulsant activity of (+)BW373U86 and its effects in the forced swim assay. This suggested a delta-opioid mechanism for both effects. Midazolam prevented convulsions but did not prevent activity in the forced swim assay. Rats tolerant to the convulsive effects of (+)BW373U86 still displayed antidepressant-like effects.
CONCLUSION: delta-Mediated convulsions do occur in rats and can be prevented without affecting the delta-mediated effects in the forced swim assay. Therefore the convulsant activity of (+)BW373U86 and possibly other non-peptidic delta-agonists is not required for activity in the forced swim assay.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12373418     DOI: 10.1007/s00213-002-1179-y

Source DB:  PubMed          Journal:  Psychopharmacology (Berl)        ISSN: 0033-3158            Impact factor:   4.530


  42 in total

Review 1.  Ligand-directed signalling within the opioid receptor family.

Authors:  Amynah A Pradhan; Monique L Smith; Brigitte L Kieffer; Christopher J Evans
Journal:  Br J Pharmacol       Date:  2012-11       Impact factor: 8.739

2.  Exploring the Backbone of Enkephalins To Adjust Their Pharmacological Profile for the δ-Opioid Receptor.

Authors:  Arnaud Proteau-Gagné; Véronique Bournival; Kristina Rochon; Yves L Dory; Louis Gendron
Journal:  ACS Chem Neurosci       Date:  2010-09-17       Impact factor: 4.418

3.  Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys.

Authors:  Ingela Danielsson; Maciej Gasior; Glenn W Stevenson; John E Folk; Kenner C Rice; S Stevens Negus
Journal:  Pharmacol Biochem Behav       Date:  2006-11-15       Impact factor: 3.533

4.  Dissociation between sex differences in the immunological, behavioral, and physiological effects of kappa- and delta-opioids in Fischer rats.

Authors:  Jay C Elliott; Mitchell J Picker; Andrew J Sparrow; Donald T Lysle
Journal:  Psychopharmacology (Berl)       Date:  2006-01-06       Impact factor: 4.530

Review 5.  30 years of dynorphins--new insights on their functions in neuropsychiatric diseases.

Authors:  Christoph Schwarzer
Journal:  Pharmacol Ther       Date:  2009-05-28       Impact factor: 12.310

6.  Peptidic delta opioid receptor agonists produce antidepressant-like effects in the forced swim test and regulate BDNF mRNA expression in rats.

Authors:  Mary M Torregrossa; Emily M Jutkiewicz; Henry I Mosberg; Gianfranco Balboni; Stanley J Watson; James H Woods
Journal:  Brain Res       Date:  2005-12-20       Impact factor: 3.252

7.  Effects of the δ opioid receptor agonist SNC80 on pain-related depression of intracranial self-stimulation (ICSS) in rats.

Authors:  S Stevens Negus; Marisa B Rosenberg; Ahmad A Altarifi; Robert H O'Connell; John E Folk; Kenner C Rice
Journal:  J Pain       Date:  2012-03-15       Impact factor: 5.820

Review 8.  Recent advances on the δ opioid receptor: from trafficking to function.

Authors:  Louis Gendron; Nitish Mittal; Hélène Beaudry; Wendy Walwyn
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

9.  Comparison of peptidic and nonpeptidic delta-opioid agonists on guanosine 5'-O-(3-[35S]thio)triphosphate ([35S]GTPgammaS) binding in brain slices from Sprague-Dawley rats.

Authors:  Emily M Jutkiewicz; Nicholas P Walker; John E Folk; Kenner C Rice; Philip S Portoghese; James H Woods; John R Traynor
Journal:  J Pharmacol Exp Ther       Date:  2004-12-01       Impact factor: 4.030

10.  In vitro and in vivo pharmacological profile of UFP-512, a novel selective delta-opioid receptor agonist; correlations between desensitization and tolerance.

Authors:  B Aguila; L Coulbault; M Boulouard; F Léveillé; A Davis; G Tóth; A Borsodi; G Balboni; S Salvadori; P Jauzac; S Allouche
Journal:  Br J Pharmacol       Date:  2007-11-05       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.